Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal delivery of beta-blockers.

Mohammed Aqil1, Yasmin Sultana, Asgar Ali

  • 1Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi-110062, India. aqilmalik@yahoo.com

Expert Opinion on Drug Delivery
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-generation structured lipid systems in plant-based meat: oleogels, emulsion architectures, and sensory optimization.

NPJ science of food·2026
Same author

Traditional antidiabetic medicinal plants of Himachal Pradesh: ethnomedicinal evidence and drug-discovery potential.

Frontiers in nutrition·2026
Same author

Trichoderma combined with palm kernel shell biochar promotes root health and rhizosphere biodiversity in young oil palm seedlings infected with <i>Ganoderma boninense</i>.

Frontiers in microbiomes·2026
Same author

Cyclodextrins-Phospholipids Complex Loaded Nanofibers for Improved Oral Bioavailability and Brain Targeting for Management of Stress and Anxiety.

CNS & neurological disorders drug targets·2026
Same author

Chorioallantoic membrane assay demonstrating pro-angiogenic properties of BRAF inhibitor: a tool to treat chronic wounds.

Growth factors (Chur, Switzerland)·2026
Same author

Proximal Femur Stabilization Using Prolene Mesh in Girdlestone Resection Arthroplasty: A Case Report.

Journal of orthopaedic case reports·2026

Beta-blockers, widely used cardiovascular drugs, face limitations with conventional forms. Transdermal delivery systems offer a promising alternative, enhancing patient compliance and reducing side effects for beta-adrenoceptor blocking drugs.

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Cardiovascular Medicine

Background:

  • Beta-blockers are a cornerstone in cardiovascular therapy, frequently administered via conventional dosage forms.
  • Conventional beta-blocker formulations present challenges such as hepatic first-pass metabolism, variable absorption, frequent dosing, and poor patient compliance.
  • Transdermal drug delivery systems (TDDS) are being explored to overcome these limitations and improve therapeutic outcomes.

Purpose of the Study:

  • To provide a comprehensive overview of transdermal research for beta-adrenoceptor blocking drugs (beta-blockers).
  • To highlight the potential of TDDS to address the drawbacks associated with conventional beta-blocker administration.
  • To review advancements in skin permeation and formulation development for various beta-blockers.

Related Experiment Videos

Main Methods:

  • Review of existing laboratory-level research on beta-blocker skin permeation.
  • Investigation of novel drug delivery strategies, including penetration-enhancing techniques.
  • Analysis of transdermal formulation development for a range of beta-blockers.

Main Results:

  • Significant research efforts are dedicated to developing transdermal beta-blocker formulations.
  • Penetration-enhancing strategies like iontophoresis, electroporation, microneedles, and sonophoresis show promise for effective transdermal delivery.
  • Despite extensive research, no beta-blocker has yet been marketed as a transdermal system.

Conclusions:

  • Transdermal delivery systems offer a viable strategy to improve the therapeutic profile of beta-blockers.
  • Advanced techniques are crucial for overcoming skin barrier challenges and achieving efficient transdermal permeation.
  • Further development and clinical translation are needed to realize the potential of consumer-friendly transdermal beta-blocker dosage forms.